» Articles » PMID: 27439912

IL-10+ Regulatory B Cells Are Enriched in Cord Blood and May Protect Against CGVHD After Cord Blood Transplantation

Abstract

Cord blood (CB) offers a number of advantages over other sources of hematopoietic stem cells, including a lower rate of chronic graft-versus-host disease (cGVHD) in the presence of increased HLA disparity. Recent research in experimental models of autoimmunity and in patients with autoimmune or alloimmune disorders has identified a functional group of interleukin-10 (IL-10)-producing regulatory B cells (Bregs) that negatively regulate T-cell immune responses. At present, however, there is no consensus on the phenotypic signature of Bregs, and their prevalence and functional characteristics in CB remain unclear. Here, we demonstrate that CB contains an abundance of B cells with immunoregulatory function. Bregs were identified in both the naive and transitional B-cell compartments and suppressed T-cell proliferation and effector function through IL-10 production as well as cell-to-cell contact involving CTLA-4. We further show that the suppressive capacity of CB-derived Bregs can be potentiated through CD40L signaling, suggesting that inflammatory environments may induce their function. Finally, there was robust recovery of IL-10-producing Bregs in patients after CB transplantation, to higher frequencies and absolute numbers than seen in the peripheral blood of healthy donors or in patients before transplant. The reconstituting Bregs showed strong in vitro suppressive activity against allogeneic CD4(+) T cells, but were deficient in patients with cGVHD. Together, these findings identify a rich source of Bregs and suggest a protective role for CB-derived Bregs against cGVHD development in CB recipients. This advance could propel the development of Breg-based strategies to prevent or ameliorate this posttransplant complication.

Citing Articles

POU2F2 B cells enhance antitumor immunity and predict better survival in non small cell lung cancer.

Shi H, Wang W, Luo J, Song G, Han R Sci Rep. 2025; 15(1):6549.

PMID: 39994401 PMC: 11850725. DOI: 10.1038/s41598-025-90817-3.


Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives.

Hashimoto A, Hashimoto S Cancers (Basel). 2024; 16(23).

PMID: 39682280 PMC: 11640101. DOI: 10.3390/cancers16234094.


Ex vivo-generated human CD1c regulatory B cells by a chemically defined system suppress immune responses and alleviate graft-versus-host disease.

Bao Y, Liu J, Li Z, Sun Y, Chen J, Ma Y Mol Ther. 2024; 32(12):4372-4382.

PMID: 39489917 PMC: 11638867. DOI: 10.1016/j.ymthe.2024.10.026.


MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy.

Fey R, Nichols R, Tran T, Vandenbark A, Kulkarni R Cancers (Basel). 2024; 16(9).

PMID: 38730725 PMC: 11082995. DOI: 10.3390/cancers16091773.


Secreted IgM modulates IL-10 expression in B cells.

McGettigan S, Aira L, Kumar G, Ballet R, Butcher E, Baumgarth N Nat Commun. 2024; 15(1):324.

PMID: 38182585 PMC: 10773282. DOI: 10.1038/s41467-023-44382-w.


References
1.
He Y, Qian H, Liu Y, Duan L, Li Y, Shi G . The roles of regulatory B cells in cancer. J Immunol Res. 2014; 2014:215471. PMC: 4060293. DOI: 10.1155/2014/215471. View

2.
Jacobson C, Sun L, Kim H, McDonough S, Reynolds C, Schowalter M . Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20(5):668-75. PMC: 3985384. DOI: 10.1016/j.bbmt.2014.01.021. View

3.
Stanevsky A, Goldstein G, Nagler A . Umbilical cord blood transplantation: pros, cons and beyond. Blood Rev. 2009; 23(5):199-204. DOI: 10.1016/j.blre.2009.02.001. View

4.
Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman D . Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol. 2001; 167(2):1081-9. DOI: 10.4049/jimmunol.167.2.1081. View

5.
Blair P, Norena L, Flores-Borja F, Rawlings D, Isenberg D, Ehrenstein M . CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010; 32(1):129-40. DOI: 10.1016/j.immuni.2009.11.009. View